Tessera Therapeutics Lands $150m Regeneron Gene Therapy Deal - Boston ...

Regeneron Puts Up $150M to Partner on Tessera Gene-Editing Med for Rare Liver & Lung Disorder

Regeneron Pharmaceuticals will share in development of Tessera Therapeutics’ TSRA-196, a Phase 1-ready gene-editing therapy for alpha-1 antitrypsin deficiency (AATD). Other companies developing genetic medicines for this rare disease include Beam Therapeutics, Wave Life Sciences, Korro Bio, and AIRNA. The post Regeneron Puts Up $150M to Partner on Tessera Gene-Editing Med for Rare Liver & Lung Disorder appeared first on MedCity News.

Regeneron Invests $150M In Tessera To Advance One-Time Gene Therapy - Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Tessera Therapeutics, Inc., on Monday announced a global collaboration to develop and commercialize TSRA-196. • REGN is lagging behind market performance. Stay ahead of the curve here. TSRA-196 is Tessera’s lead investigational in vivo Gene Writing program for alpha-1 antitrypsin deficiency (AATD), an inherited monogenic disease that can affect the lungs, liver or both organs. Alpha-1 antitrypsin…

Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)

TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the...

Regeneron Invests $150 Million In Tessera To Advance One-Time Gene Therapy For Rare Genetic Disorder

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Tessera Therapeutics, Inc., on Monday announced a global collaboration to develop and commercialize TSRA-196. • REGN is lagging behind market performance. Stay ahead of the curve here. TSRA-196 is Tessera’s lead investigational in vivo Gene…

Regeneron and Tessera join forces to forge in vivo AATD gene therapy  - Pharmaceutical Technology

If approved, Regeneron and Tessera's TSRA-196 could become the first curative therapy to reach patients with AATD, who have traditionally relied on augmentation therapies.